News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
In First Swiss IPO This Year, Arpida Brings In CHF97.2M
October 19, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Pricing its initial public offering at CHF18 per share - the bottom of its expected range of CHF18 to CHF22 - Arpida AG realized gross proceeds of CHF97.2 million (US$80.9 million) from its debut on the Swiss Stock Exchange May 4.
Twitter
LinkedIn
Facebook
Email
Print
Europe
MORE ON THIS TOPIC
Insights
Nordic biotech’s next act: From fragmentation to global force
July 23, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Manufacturing
Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesity
July 21, 2026
·
2 min read
·
Nick Paul Taylor
Insights
Golden Triangle still dominates, but talent and capital gaps slow biotech growth
July 1, 2026
·
3 min read
·
Jennifer C. Smith-Parker
Insights
The Golden Triangle and the gaps: Rethinking UK biotech
June 25, 2026
·
1 min read
·
Jennifer C. Smith-Parker